Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.83
TROV's Cash to Debt is ranked higher than
60% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. TROV: 1.83 )
TROV' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 1.83

Equity to Asset 0.29
TROV's Equity to Asset is ranked higher than
54% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. TROV: 0.29 )
TROV' s 10-Year Equity to Asset Range
Min: -9.76   Max: 0.75
Current: 0.29

-9.76
0.75
F-Score: 2
Z-Score: 0.95
M-Score: -5.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -5337.86
TROV's Operating margin (%) is ranked higher than
51% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. TROV: -5337.86 )
TROV' s 10-Year Operating margin (%) Range
Min: -5337.5   Max: -1077.56
Current: -5337.86

-5337.5
-1077.56
Net-margin (%) -5116.07
TROV's Net-margin (%) is ranked higher than
51% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. TROV: -5116.07 )
TROV' s 10-Year Net-margin (%) Range
Min: -5116.07   Max: -867.83
Current: -5116.07

-5116.07
-867.83
ROE (%) -94.02
TROV's ROE (%) is ranked higher than
58% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. TROV: -94.02 )
TROV' s 10-Year ROE (%) Range
Min: -104.7   Max: -99.68
Current: -94.02

-104.7
-99.68
ROA (%) -47.92
TROV's ROA (%) is ranked higher than
62% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. TROV: -47.92 )
TROV' s 10-Year ROA (%) Range
Min: -288.72   Max: -51.11
Current: -47.92

-288.72
-51.11
ROC (Joel Greenblatt) (%) -1818.69
TROV's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. TROV: -1818.69 )
TROV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -25886.96   Max: -1878.69
Current: -1818.69

-25886.96
-1878.69
» TROV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TROV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 20.30
TROV's P/B is ranked lower than
57% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. TROV: 20.30 )
TROV' s 10-Year P/B Range
Min: 3.26   Max: 69.3
Current: 20.3

3.26
69.3
P/S 890.00
TROV's P/S is ranked lower than
60% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 37.39 vs. TROV: 890.00 )
TROV' s 10-Year P/S Range
Min: 80   Max: 890
Current: 890

80
890
EV-to-EBIT -12.90
TROV's EV-to-EBIT is ranked higher than
58% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TROV: -12.90 )
TROV' s 10-Year EV-to-EBIT Range
Min: -27.2   Max: -3
Current: -12.9

-27.2
-3
Current Ratio 6.18
TROV's Current Ratio is ranked higher than
79% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. TROV: 6.18 )
TROV' s 10-Year Current Ratio Range
Min: 0.08   Max: 15.13
Current: 6.18

0.08
15.13
Quick Ratio 6.18
TROV's Quick Ratio is ranked higher than
80% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. TROV: 6.18 )
TROV' s 10-Year Quick Ratio Range
Min: 0.08   Max: 15.13
Current: 6.18

0.08
15.13
Days Sales Outstanding 74.30
TROV's Days Sales Outstanding is ranked higher than
80% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. TROV: 74.30 )
TROV' s 10-Year Days Sales Outstanding Range
Min: 74.3   Max: 140.06
Current: 74.3

74.3
140.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.70
TROV's Price/Net Cash is ranked higher than
64% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 86.70 vs. TROV: 24.70 )
TROV' s 10-Year Price/Net Cash Range
Min: 5.68   Max: 77
Current: 24.7

5.68
77
Price/Net Current Asset Value 24.70
TROV's Price/Net Current Asset Value is ranked higher than
62% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 39.00 vs. TROV: 24.70 )
TROV' s 10-Year Price/Net Current Asset Value Range
Min: 5.63   Max: 69.3
Current: 24.7

5.63
69.3
Price/Tangible Book 20.20
TROV's Price/Tangible Book is ranked lower than
54% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. TROV: 20.20 )
TROV' s 10-Year Price/Tangible Book Range
Min: 3.8   Max: 62.6
Current: 20.2

3.8
62.6
Price/Median PS Value 2.60
TROV's Price/Median PS Value is ranked higher than
71% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. TROV: 2.60 )
TROV' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 1.44
Current: 2.6

0.31
1.44
Earnings Yield (Greenblatt) -7.50
TROV's Earnings Yield (Greenblatt) is ranked higher than
62% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. TROV: -7.50 )
TROV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -18.1   Max: 0
Current: -7.5

-18.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:XE7A.Germany,
TrovaGene Inc was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology. As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The Company is leveraging its proprietary urine-based molecular diagnostic technology for the detection of cell-free DNA and RNA originating from diseased cell death that can be isolated from urine and detected to improve disease management. These genetic materials are also collectively referred to as cell-free nucleic acids, which result when cells in the body die and release their DNA or RNA into the bloodstream. Its fundamental urine-based molecular diagnostic platform is protected by a intellectual property portfolio. The Company's developed intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly its proprietary non-naturally occurring primers. As of February 28, 2014, its property portfolio consists of over 130 issued patents and over 47 pending patent applications. The Company faces direct competition in the area of transrenal cell-free DNA or RNA detection and analysis is precluded by its growing patent estate. Its competitors include medical diagnostic companies, of which have financial, technical, and marketing resources greater than its resources.
» More Articles for TROV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
TROVAGENE, INC. Files SEC form 8-K, Other Events May 04 2015
Cost Benefit Analysis of Trovagene's Precision Cancer Monitoring Solution to Be Presented at the... May 04 2015
Cost Benefit Analysis of Trovagene's Precision Cancer Monitoring Solution to Be Presented at the... May 04 2015
Is it a Miss for TrovaGene (TROV) This Earnings Season? - Analyst Blog May 01 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Apr 28 2015
Trovagene Schedules Release of First Quarter 2015 Financial Results and Investor Conference Call Apr 28 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Apr 23 2015
Trovagene's Urine-Based HPV Assay to Be Featured in Presentation at the 13th Annual Cervical Cancer... Apr 23 2015
Trovagene's Urine-Based HPV Assay to Be Featured in Presentation at the 13th Annual Cervical Cancer... Apr 23 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Apr 20 2015
TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog Apr 20 2015
Poster Presentations at 2015 AACR Annual Meeting to Highlight Clinical Utilities and Advantages of... Apr 20 2015
Poster Presentations at 2015 AACR Annual Meeting to Highlight Clinical Utilities and Advantages of... Apr 20 2015
Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of... Apr 17 2015
Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of... Apr 17 2015
4 Fresh Biotech Stock Picks With Targets 50% to 100% Higher Apr 04 2015
TROVAGENE, INC. Financials Mar 19 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Mar 18 2015
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer Mar 18 2015
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer Mar 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK